Visual prognosis of vitrectomy for polypoidal choroidal vasculopathy with breakthrough vitreous hemorrhage

来源期刊： Eye Science | 2024年1月第1卷第1期： 39-49 发布时间：2024-01-01 收稿时间：2024/4/25 15:06:54 阅读量：1000

作者：: 蔡晨希,

Jin-Li Cui,

Qiang Wang,

Tao Li,

Bing-Qian Liu,

Zhen-Qiang Lin,

Xiao-Mei Xiong,

Ze-Hao Liu,

Ying Lin,

关键词：: polypoidal choroidal vasculopathy vitreous hemorrhage vitrectomy visual acuity; polypoidal choroidal vasculopathy vitreous hemorrhage vitrectomy visual acuity

DOI：: 10.12419/es24030203

Aim: The objective of this study was to investigate the prognosis of massive vitreous hemorrhage(VH) secondary to polypoidal choroidal vasculopathy(PCV) after vitrectomy.

Methods: Forty-nineeyes in 48 patients with PCV and breakthrough VH who underwent 23-gauge pars plana vitrectomy between January 2015 and December 2020 were enrolled. The main outcome parameters were best-corrected visual acuity, postoperative adverse events, and reoperation.

Results:The average follow-up time was 20.0±15.82 months. The average preoperative best-corrected visual acuity (BCVA) was 2.12±0.65 logarithm of the minimum angle of resolution (logMAR), the BCVA at six monthswas 1.65±0.64 logMAR, and the six-month follow-up BCVA was 1.67±0.76 logMAR. Compared to the average preoperative BCVA, the six-months and last follow-up BCVA after vitrectomy improved (P<0.05). The BCVAat the fnal follow-up was better than 1.3logMAR only in 14 eyes (28.6%). Postoperative complications were observed in 10 eyes (20.4%), including recurrent retinal detachment, recurrent vitreous hemorrhage, macular hole, hyphema and lens dislocation. Fourteen eyes(28.6%) underwent cataract surgery procedure an average of 10.16±5.14 months after vitrectomy. BCVAone week and three monthsafter cataract surgery improved compared toBCVAbefore cataract surgery (P<0.05). Hypertension was associated with BCVAsix months after vitrectomy (P=0.017). The BCVA at baseline and three months after PPV were worse in patients who underwent vitrectomy combined with silicone oil filling (P<0.05). Eyes with postoperative complications had worse BCVA at six months, 12 months, and at the final follow-up after PPV (P<0.05).The duration of VH is related to the BCVA12 months after PPV visual acuity after surgery. Patients who underwent vitrectomy within one month of the onset of vitreous hemorrhage had better BCVA 12 months after vitrectomy than those who underwent vitrectomy surgery one month later (P=0.015).

Conclusions: Although the prognosis of vitrectomy varies greatly, cataract surgery could be considered to improve BCVAif polypoidal lesions are inactive six months after vitrectomy.

Introduction

Polypoid choroidal vasculopathy (PCV), characterized by subretinal orange-red nodular lesions on the fundus, recurrent submacular hemorrhage (SMH), and serous or hemorrhagic retinal pigment epithelial detachment (PED), is a risk factor for severe visual impairment in Asian populations.Large submacular hemorrhages may develop into dense breakthrough vitreous hemorrhages. Polypoid choroidal vasculopathy with breakthrough vitreous hemorrhage (PCVVH) was first reported by Kleiner in 1985,with 4.5-19.9% of patients with PCV running the risk of developingvitreous hemorrhage.^[1-3] To date, vitrectomy is the primary treatment method, although the prognosis of vitrectomy for PCVVH varies greatly. In addition, a consensus on the timing of this operation, namely the duration from vitreous hemorrhage to perform vitrectomy, as well as whether cataract surgery and intraocular lens implantation can improve the vision or not, is lacking. Furthermore, few relevant studies exist in the literature. Therefore, this study aimed to investigate the prognosis and risk factors for vitrectomy for massive vitreous hemorrhage (VH) secondary to polypoidal choroidal vasculopathy.

Materials and Methods

This was a retrospective study, and ethical approval was obtained from the Institutional Review Board of Zhongshan Ophthalmic Center. The clinical characteristics of 49 eyes of 48 patients with polypoidal choroidal vasculopathy and breakthrough vitreous hemorrhage treated with a 23-gauge pars plana vitrectomy(PPV) between January 2015 and December 2020 were evaluated.

The inclusion criteria were as follows: (1)diagnosis of PCV based on the results of fundus examination, B ultrasound, optical coherence tomography (OCT), fundus fuorescein angiography (FFA), and indocyanine green angiography (ICGA),both preoperatively and postoperatively, and the presence of orange red polypoidal lesions during the operation; (2)vision loss due to PCVVHwas treated with 23-gauge PPV; and (3)the follow-up durationwas at least six months.

Similarly, the exclusion criteria were as follows: (1)traumatic vitreous hemorrhage; (2) other ocular diseases that could affect visual acuity, such as primary glaucoma, optic neuritis, age-related macular degeneration(AMD), retinal vein occlusion, choroidal melanoma, and retinal vasculitis; and (3) a medical history of photodynamic therapy(PDT) or PPV.

All patients underwent a comprehensive eye examination, including best-corrected visual acuity (BCVA), slit-lamp microscopy, and B-scan before surgery. The patients also underwent 23-gauge PPV, including central and peripheral vitrectomies, performed by multiple skilled surgeons. We used a wide-angle viewing system for PPV and identified the peripheral retina during the peripheral vitrectomy. If subretinal hemorrhage was observed during surgery without retinal tears, this was not treated due to the signifcant damage caused by clearing subretinal hemorrhage. According to the surgeon’s judgment, silicone oil or C3F8 was used to fill the vitreous cavity. In cases with retinal tears or poor fundus conditions, silicone oil is generally chosen. Epiretinal membrane enucleation was performed if a macular epiretinal membrane was observed. The following data was collected from each of the patients enrolled : BCVAbefore and after surgery, duration of VH until surgery, hypertension, diabetes, anticoagulant use, smoking history, anti-vascular endothelial growth factor (VEGF) use, spectrum OCT (SD-OCT; Heidelberg, Germany), postoperative complications, and secondary surgery during follow-up.

Statistical analysis

BCVA was measured usingan early treatment diabetic retinopathy study(EDTRS) chart and converted to the logarithm of the minimum angle of resolution (logMAR) scale for statistical analysis. No light perception was set at 3.5 logMAR, light perception was set at 3.2 logMAR, hand movement(HM) was set at 2.3 logMAR, and counting fngers (CF) was set at 1.85 logMAR, according to a previous method.^[4]
A paired t-test was used to compare the visual improvement and differences between the BCVA of post-vitrectomy at three, six, and 12 monthsand at the final follow-up from the BCVA of baseline pre-vitrectomy. The BCVAof post-cataract surgery at one week and three months was compared to the BCVAof baseline pre-cataract surgery performed after vitrectomy. The prognostically relevant factors were grouped, and independent sample t-tests were used to compare the differences in BCVAat each time point. One-way analysis of variance (ANOVA) was used to compare the BCVAat baseline and post-vitrectomy at three, six, and 12 months and at a final follow-up between the age groups and BCVAgroups. Avalue of P≤0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows (version 17.0; SPSS Inc., Chicago, IL, USA).

Results

This study included 49 eyes in 48 patients.The clinical characteristics of the enrolled patients are presented in Table 1. Among the 48 patients, 31 (64.6%) were male and 17 (35.4%) were female. The average follow-up period was 20.0±15.82 months. The average age of onset was 62.1±9.65 years (range 36-87 years), which was mostly concentrated in the range from 50 to 70 years. Atotal of 44 patients (91.7%) were diagnosed with monocular PCV, while four patients (8.3%) were diagnosed with binocular PCV, consistent with reports in the literature.^[1,5-6] Fourteen patients (29.2%) had hypertension,10 patients (20.8%) had diabetes. Six patients (12.2%) took anticoagulant drugs before the onset of VH, and seven patients (14.3%) hada smoking history.Before vitrectomy, 33 patients (68.8%) were diagnosed with cataracts, and three patients had undergone phacoemulsification combined with intraocular lens implantation. None of the patients enrolled had high myopia.The average axis of the left eye was 23.48±0.70 mm,and that of the right eye was 22.60±4.76 mm. Nocases of high myopia were observed in this study.

Table 1 Clinical characteristics of patients with massive vitreous hemorrhage secondary to polypoidal choroidal vasculopathy

All 49 eyes of 48 patients with PCVVH were treated with 23-gauge PPV, among which eight eyes were combined with silicone oil filling,one eye was treated with C3F8,one eye was treated with phacoemulsification and intraocular lens implantation, 28 eyes underwent epiretinal membrane enucleation, and 12 eyes underwentendophotocoagulation. The duration from the onset of visual symptoms to vitrectomy was defined as the period of vitreous hemorrhage when patients complained of decreased vision, blurred vision, and dark shadows. The average duration of VH was 3.84±8.55 months(range, 0.5-60 months). The average preoperative BCVA was 2.12±0.65(logMAR; range, 0.4-3.5), wherein BCVAat three months after PPV was 1.53±0.72(logMAR; range, 0.1-3.20), at six months was 1.65±0.64(logMAR; range, 0.49-3.2), at 12 months was 1.58±0.80(logMAR; range, 0.22-3.20), and at the last follow-up was 1.67±0.76(logMAR; range, 0.1-3.20).Compared with the average preoperative BCVA, BCVA at three, six, and 12 monthsand at the last follow-up after vitrectomy improved (P<0.05)(Table 2). Compared with the average preoperative BCVA, the BCVAof 35 eyes was improved, six eyes were worse and eight eyes were stable with preoperative BCVAat the fnal follow-up. The BCVAatthe fnal follow-up was better than 1.3logMAR only in 14 eyes (28.6%).

Table 2 BCVA at baseline and three, six, and 12 months final follow-up after vitrectomy

Postoperative complications were observed in 10 eyes (20.4%) and included recurrent retinal detachment, vitreous hemorrhage, macular holes, hyphema, and lens dislocation.Nine eyes underwent vitrectomy surgery because of recurrent retinal detachment at 10.82±7.19 months (range 2.1-25 months) after the frst vitrectomysurgery, three of which were with recurrent vitreous hemorrhage at the average of 7.6 months (range 6.3-9.6 months) after the first vitrectomy surgery. A macular hole at 3.7 months after vitrectomy surgery was observed in one eye, lens dislocation at the average of 5.7 months (range 2-9.4 months) after vitrectomy surgerywas observed in two eyes, and hyphema at the average of 5.8 months (range 1.4-9.6 months) after vitrectomy surgery was observed in three eyes.

Eight eyes underwent vitrectomy combined with silicone oil flling, and the silicone oil was taken out at 11.99±6.25 months (range 3.8-25 months) after surgery. Four eyes were observed recurrent retinal detachment after removing silicone oil at 11.54±8.04 months(range 3.8-25 months).

Fourteen eyes (28.6%) were subjected to phacoemulsifcation and intraocular lens implantation in an average time of 10.16±5.14 months (range 1.97-21.43 months) after vitrectomy. Six eyes underwent vitrectomy combined with cataract surgery dueto postoperative complications. Compared with the BCVAbefore cataract surgery, the final BCVAwas stable or improved in 13 eyes, increased in one eyes. BCVAat one week and three months post-cataract surgery was improved compared with BCVAbefore cataract surgery (P<0.05)(Table 3). Among these 14 eyes, the BCVAatthe final follow-up was better than 1.3logMAR only in six eyes (28.6%); the fnal follow-up BCVAof two eyes improved compared with the blind standard, and the other two eyes improved compared with the low visual acuity standard.

Table 3 BCVA before cataract surgery and 1 week and 6 months after cataract surgery

Patients were grouped according to the duration of VH(≤1 month or >1 month), gender (male or female), age group(<50, 50-59, 60-69, ≥70), and the presence or absence of the following clinical characteristics: hypertension, diabetes, preoperative use of anticoagulants, smoking history, preoperative anti-VEGF, postoperative anti-VEGF, vitrectomy combined silicone oil filling, postoperative complications, and patients who underwent cataract surgery. The prognostic factors related to BCVAatthe baseline, three, six, and 12 monthsand at the fnal follow-up were screened (Table 4). Hypertension was associated with BCVAsix months after vitrectomy (P=0.017). The BCVAat baseline and three months after PPV were worse in patients who underwent vitrectomy combined with silicone oil filling (P<0.05).Eyes with postoperative complications had worse BCVA at six months, 12 months, and at the fnal follow-up after PPV(P<0.05).The duration of VH is related to the BCVA 12 months after PPV visual acuity after surgery. Patients who underwent vitrectomywithin one month of the onset of vitreous hemorrhage had better BCVA12 months after vitrectomy than those who underwent vitrectomy surgery one month later (P=0.015). No statistically significant correlation was observed between sex, age, diabetes, use of anticoagulants, smoking history, preoperative anti-VEGF, postoperative anti-VEGF, cataract surgery, and BCVA(P>0.05).

Table 4 Factors related to visual prognosis after PPV surgery

Patients were separated into three groups, 3.5-3.2logMAR(Group A), 2.3-1.85 logMAR(Group B), and >1.85 logMAR(Group C), according to BCVA.Then, the BCVAof post-vitrectomy at three, six, and 12 months and at the fnal follow-up between the three groups was compared. Significant differences were observed in terms of the visual acuity between group Aand group B at three, six, and 12 months and at the fnal follow-up,as well as between group Aand group C(P<0.05). There was no statistically signifcant diference in visual acuity between group B and group C (P>0.05). Extremely poor preoperative vision, with or without light perception, is associated with poor vision after surgery. Therefore, when patients with PCVVH have extremely poor vision, it is necessary to consider whether vitrectomy should be performed.

Discussion

At present, the pathogenic mechanism of PCV remains unclear. Kimura et al.^[7] found that 43% of patients with SMH secondary to PCV had a history of hypertension, and 9% had a long history of antiplatelet use due to cardiovascular disease.In the present study, 14 patients (29.2%) had a history of hypertension, which was associated withpoor BCVAsix months after PPV (P<0.05). Six patients took medicines, including aspirin and some Chinese medicines, such as Danshen dripping pills andXueshuantong, before the onset of vitreous hemorrhage. Five of the patients enrolled took these drugs for more than half a year. However, whether the patients took these drugs was not signifcantly related to BCVAafter PPV (P>0.05). Further studies will be needed to determine whether anticoagulant use is associated with PCVVH.Tao Li et al. found that higher WBC, higher AST/ALT, and longer APTT are independent serum risk factors of PCVVH.^[8] It is worth noting that the difference between the proportions of male and female in the PCVVH group was strongly positive. In Asian populations, the smoking rate in men is significantly higher than that in women, which may be a reason for the diference in the incidence rate ofAMD between men and women. AJapanese study found that the incidence of late AMD was significantly higher in males than in females, and that current smoking was associated with late AMD after adjusting for age and gender.^[9] AMalay study showed that earlyAMD was more common in men than in women. After adjusting for age and smoking, the diference was still signifcant,^[10] suggesting that smoking could not fully explain the diference in incidence rates between men and women.

There is no consensus on the timing of surgery for patients with PCVVH or whether anti-VEGF therapy is required before surgery in the clinical setting.Some surgeons tend to inject anti-VEGF into the vitreous after the onset of vitreous hemorrhage and then perform PPV surgery after the vitreous hemorrhage is slightly reduced, which could reduce the difficulty of the operation. Chen et al.^[11] reported that anti-VEGF injection into the vitreous before PPV surgery could help reduce the frequency of anti-VEGF treatments and postoperative complications and improve short-term vision after surgery.Quanyong Yifound that perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications.^[12] Previous animal experiments have shown that subretinal hemorrhage lasts for seven days, causing irreversible damage to the photoreceptor cells and retinal pigment epithelial(RPE) atrophy. Subsequently, local retinal necrosis occurs within 14 days, which allows red blood cell fragments to pass through the damaged retina, causing vitreous hemorrhage.^[13-14] Kimura et al.^[15] proposedan optimal operation time for SMH secondary to PCV of 7-10 days after the onset of SMH. On the one hand, a premature intervention can lead to recurrent bleeding after operation. However, on the other hand, if the intervention time is too late, this can cause irreversible damage to the retina, leading to poor postoperative vision. Nevertheless, the duration of VH in the enrolled patients ranged from half to six months. Therefore, we divided them into groups according to whether the duration of VH exceeded one month or not, and found that patients who underwent vitrectomywithin one month of the onset of VH had better BCVA12 months after vitrectomy than those who underwent vitrectomyone month later (P=0.015). There was no statistically significant relation between preoperative anti-VEGF levels and BCVA(P>0.05). If PPV surgery is performed early, the retina can easily be damaged owing to a thick subretinal hemorrhage. Blood cell fragments stay in the vitreous for a long time, which may cause irreversible toxic effects on the retina, and damage the retina and RPE layer. Thus, we propose that vitrectomy surgery should be performed within one month of the onset of massive vitreous hemorrhage in order to improve vision after surgery.

PPV is theprimary treatment for PCVVH. Zhao et al.^[16] retrospectively analyzed 103 eyes with PCVVH and found that BCVA was significantly better after PPV thanbefore surgery.Lin et al.^[17] studied 17 eyes with PCVVH that underwent vitrectomy, of which visual acuity improved in 16 eyes. Severe cataract and macular scarring causepoor visual acuity. In the present study,BCVAat three, six, and 12 months and at the last follow-up after vitrectomy improved compared to the average preoperative BCVA(P<0.05), consistent with the results of previous studies.^[16-20] However, the visual acuity of patients with PCVVH varies considerably after vitrectomy, with most patients maintaining a low level of visual acuity. As shown in Figure 1, PCVVH is characterized by large polypoid lesions and strong activity. If the lesion does not involve the macula, the visual prognosis is better. In our study, the BCVAranged from 0.1 logMAR to 3.2 logMAR at the final follow-up. The BCVA atthe final follow-up was better than 1.3logMAR only in 14 eyes (28.6%).You-Xin Chen et al. found thathemorrhagic retinal detachment, baseline central macular thickness, and best-corrected visual acuity were factors associated with final best-corrected visual acuity (P < 0.05)in PCV patients.^[21] Previous studies have shown that the incidence of secondary epiretinal membranes is 16.6% and that older individuals are more likely to develop an epiretinal membrane.^[22] In this study, 58% of patients underwent epiretinal membrane enucleation, and the incidence of epiretinal membrane enucleation was much higher than that in the normal population. We speculate that this may be because PCV patients are mostly elderly individuals aged 50-70 years, with factors such as vitreous hemorrhage and retinal detachment exacerbating the progression of the epiretinal membrane.

Patients with PCVVH complained of decreased and blurred vision due to cataract complications half a year after PPV. Phacoemulsification and intraocular lens implantation can be considered to improve vision if polypoid lesions are inactive. Based on our study results, improvements were observed atone week and three months post-cataract surgerycompared tobefore surgery(P<0.05). However, vision prognosis after cataract surgery can vary significantly. In fact, long-term visual acuity in the 14 patients post-cataract surgery ranged from 0.1 logMAR to 2.3 logMAR. Compared toBCVA before cataract surgery, the final BCVA improved or stabilized in 13 eyes and increased in one eye. Among these 14 eyes, BCVAatthe final follow-up was better than 1.3logMAR only in six eyes (28.6%).

Common postoperative complications of PPV in patients with PCVVH include iatrogenic retinal tears, recurrent vitreous hemorrhage, complicated cataracts, hyphema, secondary glaucoma, macular subretinal fibrosis, retinal detachment, and choroidal detachment.^[18,23-24] Iatrogenic retinal tearsare the most common surgical complication, with an incidence of approximately 17.8%, mostly observed during the induction of posterior vitreous detachment (PVD).^[23] Studies have also reported sympathetic ophthalmia in the other eye, which is a rare postoperative complication.^[25] Postoperative complications were observed in 10 eyes (20.4%) and included recurrent retinal detachment(18.4%), vitreous hemorrhage(6.1%), macular holes (2%), hyphema(6.1%), and lens dislocation(4.1%). The peak period of postoperative complications was within one year after PPV, although one patient had recurrent retinal detachment more than two years after the first PPV. Notably, recurrent retinal detachment was observed in four eyes after silicone oil removal.Therefore, choosing theappropriate time to perform theSO removal surgery is a key factor in effectively reducing postoperative complications. Postoperative complications are another heavy blow to patients,with their vision often worsening as a result. Among patients with postoperative complications,BCVAwas mostly less than 1.3 logMAR.

All patients included in this single-center study were from the Zhongshan Ophthalmology Centre of Sun Yat-Sen University. Since this is a retrospective study, we hope that a prospective longitudinal study will shed further light on the prognosis and factors infuencingpatients with PCVVH.

When PCV is secondary to VH, visual acuity drops sharply, for which vitrectomy is the primary clinical treatment.This studyevaluates the visual prognosis of patients with PCVVH undergoing PPV surgery and shows that PPV can improve the short- and long-term visual acuity of patients with PCVVH. However, visual acuity after PPV was found to difer signifcantly, with only 28.6% of the patients showing a better long-term visual acuity than the non-blind standard. If polypoid lesions are not active, phacoemulsification and intraocular lens implantation can be considered to improve vision approximately half a year after PPV. Although some patients had a good visual acuity after cataract surgery, up to 57.1% of their vision either did not improve or deteriorated. Postoperative complications were observed in 10 eyes (20.4%).We also found that hypertension, vitrectomy combined with silicone oil filling, postoperative adverse events, and vitreous hemorrhage lasting >1 month were associated with a poor postoperative BCVA.

Correction notice

None

Acknowledgement

None

Author Contributions

(I) Conception and design: YL
(II)Administrative support: TL,BQL,YL
(III) Provision of study materials or patients: TL,BQL,YL
(IV) Collection and assembly of data: CXC and JLC
(V) Data analysis and interpretation: CXC and QW
(VI) Manuscript writing:All authors
(VII) Final approval of manuscript:All authors

Funding

This study was supported by the Bethune?Lumitin Research Funding for the young and middle-aged Ophthalmologists (grant no. BJ-LM2021014J)and the Science and Technology Program of Guangzhou, China (SL2022A03J00452).

The funding organizations had no role in the following aspects: design and conduct of the study; the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

Confict of Interests

None of the authors has any conflicts of interest to disclose. All authors have declared in the completed the ICMJE uniform disclosure form.

Patient consent for publication

Patients orally agreed to the use of their data in the present study.

Ethical Statement

All experimental protocols were approved by the ethics committee of Zhongshan Ophthalmic Center (Guangzhou, China).

Provenance and Peer Review

This article was a standard submission to our journal. The article has undergone peer review with ouranonymous review system.

Data Sharing Statement

None

OpenAccess Statement

This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

1、Kwok AK, Lai TY, Chan CW, et al. Polypoidal choroidal vasculopathy in Chinese patients[J]. Br J Ophthalmol, 2002, 86(8): 892-7.

2、Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history[J]. Am J Ophthalmol, 2002, 133(5): 639-48.

3、Hou J, Tao Y, Li XX, et al. Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients[J]. Graefes Arch Clin Exp Ophthalmol, 2011, 249(7): 975-9.

4、Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test[J]. Invest Ophthalmol Vis Sci, 2006, 47(3): 1236-40.

5、Lorentzen%20TD%2C%20SubhiY%2C%20S%C3%B8rensen%20TL%20.%20PREVALENCE%20OF%20POLYPOIDAL%20CHOROIDAL%20VASCULOPATHY%20IN%20WHITE%20PATIENTS%20WITH%20EXUDATIVE%20AGE-RELATED%20MACULAR%20DEGENERATION%3A%20Systematic%20Review%20and%20Meta-Analysis%5BJ%5D.%20Retina%2C%202018%2C%2038(12)%3A%202363-71.

6、Honda S, Matsumiya W, Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition[J]. Ophthalmologica, 2014, 231(2): 59-74.

7、Kimura S, Morizane Y, Hosokawa MM, et al. Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy[J]. Jpn J Ophthalmol, 2019, 63(5): 382-8.

8、Liu B, Lai K, Ma Y, et al. Systemic Risk Factors for Vitreous Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy[J]. Ophthalmol Ther, 2023, 12(5): 2769-80.

9、Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular dege-neration in an adult Japanese population: the Funagata study[J]. Ophthalmolo-gy, 2008, 115(8): 1376-81, 81.e1-2.

10、Kawasaki R, Wang JJ, Aung T, et al. Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study[J]. Ophthalmology, 2008, 115(10): 1735-41.

11、Chen L, Qu L, Gui Q, et al. Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage[J]. J Ocul Pharmacol Ther, 2021.

12、Chen L, Qu L, Gui Q, et al. Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage[J]. J Ocul Pharmacol Ther, 2021, 37(10): 591-6.

13、Toth CA, Morse LS, Hjelmeland LM, et al. Fibrin directs early retinal damage after experi-mental subretinal hemorrhage[J]. Arch Ophthalmol, 1991, 109(5): 723-9.

14、Lincoff H, Madjarov B, Lincoff N, et al. Pathogenesis of the vitreous cloud emanating from subretinal hemorrhage[J]. Arch Ophthalmol, 2003, 121(1): 91-6.

15、Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator[J]. Am J Oph-thalmol, 2015, 159(4): 683-9.

16、Zhao XY, Luo MY, Meng LH, et al. The Incidence, Characteristics, Management, Prognosis and Classification of Breakthrough Vitreous Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy[J]. Retina, 2020, Publish Ahead of Print.

17、Lin HC, Yang CH, Yang CM. Visual outcomes of vitrectomy for polypoidal choroidal vas-culopathy-related breakthrough vitreous haemorrhage[J]. Eye (Lond), 2014, 28(7): 797-806; quiz 7.

18、Jung JH, Lee JK, Lee JE, et al. Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy[J]. Reti-na, 2010, 30(6): 865-73.

19、Li MS, Tsen CL. Clinical features and outcomes of breakthrough vitreous hemorrhage sec-ondary to polypoidal choroidal vasculopathy[J]. PLoS One, 2022, 17(12): e0279778.

20、Inoue N, Kato A, Araki T, et al. Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey[J]. PLoS One, 2022, 17(7): e0271447.

21、Zhao XY, Luo MY, Meng LH, et al. THEINCIDENCE, CHARACTERISTICS, MAN-AGEMENT, PROGNOSIS, AND CLASSIFICATION OF BREAKTHROUGH VITREOUS HEMORRHAGE SECONDARY TO POLYPOIDAL CHOROIDAL VASCULOPATHY[J]. Re-tina, 2021, 41(8): 1675-85.

22、Xiao W, Chen X, Yan W, et al. Prevalence and risk factors of epiretinal membranes: a sys-tematic review and meta-analysis of population-based studies[J]. BMJ Open, 2017, 7(9): e014644.

23、Narayanan R, Mithal K, Jalali S, et al. Vitreous haemorrhage in massive hemorrhagic poly-poidal choroidal vasculopathy: clinical characteristics and surgical outcomes: Vitreous hemorrhage in PCV[J]. Int J Retina Vitreous, 2015, 1: 25.

24、Li ZX, Hu YJ, Atik A, et al. Long-term observation of vitrectomy without subretinal he-morrhage management for massive vitreous hemorrhage secondary to polypoidal choroidal vas-culopathy[J]. Int J Ophthalmol, 2019, 12(12): 1859-64.

25、Suetsugu T, Yasukawa T, Uemura A, et al. Sympathetic ophthalmia in fellow eye after vi-trectomy for massive subretinal hemorrhage secondary to polypoidal choroidal vasculopathy[J]. Int Med Case Rep J, 2018, 11: 293-6.

1、the Bethune·Lumitin Research Funding for the young and middle-aged Ophthalmologists (grant no. BJ-LM2021014J)

2、the Science and Technology Program of Guangzhou, China(SL2022A03J00452)